Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.41)
# 310
Out of 4,900 analysts
126
Total ratings
42.34%
Success rate
34.8%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $60 → $85 | $23.80 | +257.14% | 2 | Jul 8, 2025 | |
| MNOV MediciNova | Maintains: Buy | $6 → $5 | $1.24 | +303.23% | 2 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Neutral | $5 → $3 | $1.49 | +101.34% | 2 | May 20, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Buy | $422 → $460 | $311.14 | +47.84% | 12 | May 2, 2025 | |
| HROW Harrow | Maintains: Buy | $69 → $65 | $34.37 | +89.12% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.39 | +407.69% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $6.86 | +191.55% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $1.00 | +200.00% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $14.19 | +146.65% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $17.63 | +115.54% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $30.70 | +212.70% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $0.57 | +164.08% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $6.88 | +277.91% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $15.08 | +118.83% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $4.18 | +378.47% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $37.96 | -10.43% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $38.01 | +142.04% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $6.73 | +1,980.24% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $1.47 | +6,022.45% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $6.22 | +2,472.35% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.70 | +194.12% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.06 | +2,035.92% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.94 | +4,539.18% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $2.07 | +238.16% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $2.39 | +188,184.52% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $6.99 | +3,762.66% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $13.15 | +485.55% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $2.06 | +69,802.91% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.80 | +42.86% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $100.90 | -61.35% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.79 | +797.10% | 1 | Mar 13, 2020 |
Nektar Therapeutics
Jul 8, 2025
Maintains: Buy
Price Target: $60 → $85
Current: $23.80
Upside: +257.14%
MediciNova
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.24
Upside: +303.23%
MacroGenics
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.49
Upside: +101.34%
Madrigal Pharmaceuticals
May 2, 2025
Reiterates: Buy
Price Target: $422 → $460
Current: $311.14
Upside: +47.84%
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $34.37
Upside: +89.12%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.39
Upside: +407.69%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $6.86
Upside: +191.55%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.00
Upside: +200.00%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $14.19
Upside: +146.65%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $17.63
Upside: +115.54%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $30.70
Upside: +212.70%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.57
Upside: +164.08%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $6.88
Upside: +277.91%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $15.08
Upside: +118.83%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $4.18
Upside: +378.47%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $37.96
Upside: -10.43%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $38.01
Upside: +142.04%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $6.73
Upside: +1,980.24%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $1.47
Upside: +6,022.45%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $6.22
Upside: +2,472.35%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.70
Upside: +194.12%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.06
Upside: +2,035.92%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.94
Upside: +4,539.18%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $2.07
Upside: +238.16%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $2.39
Upside: +188,184.52%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $6.99
Upside: +3,762.66%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $13.15
Upside: +485.55%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $2.06
Upside: +69,802.91%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.80
Upside: +42.86%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $100.90
Upside: -61.35%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.79
Upside: +797.10%